In short
A clinical trial is currently underway to evaluate the effectiveness of Clebopride Hydrogen Maleate in treating Rumination Syndrome. This randomized, double-blind, placebo-controlled study aims to assess the drug's impact on patients' symptoms and overall quality of life. The trial focuses on adults with suspected Rumination Syndrome and explores various aspects of the condition using advanced diagnostic techniques.
At a glance
- Study Design
- Randomized, double-blind, placebo-controlled, crossover trial
- Condition Studied
- Rumination Syndrome
- Drug Tested
- Clebopride Hydrogen Maleate
- Dosage
- 0.5 mg three times daily (maximum 1.5 mg/day)
- Primary Outcome
- Patient's perceived overall treatment evaluation (OTE)
- Key Secondary Outcomes
- Symptom severity, number of symptom events, esophageal function measurements, quality of life
- Main Inclusion Criteria
- Adults (18+) with suspected Rumination Syndrome, normal gastro-duodenoscopy within 12 months
- Key Exclusion Criteria
- Severe erosive esophagitis, pregnancy, certain medical conditions, use of specific medications
What is Clebopride?
Clebopride, also known by its full chemical name clebopride hydrogen maleate, is a medication that belongs to a class of drugs called prokinetics. Prokinetics are medications that help improve the movement of the digestive system. In some countries, clebopride is marketed under the brand name Motilex and is available as 0.5 mg tablets.
Understanding Rumination Syndrome
Rumination syndrome is a condition where people repeatedly and unintentionally regurgitate undigested or partially digested food from the stomach back into the mouth. This happens shortly after eating and is different from vomiting. People with rumination syndrome often rechew and reswallow the food. This condition can be distressing and affect a person's quality of life.
How Clebopride May Help with Rumination Syndrome
Clebopride is being studied as a potential treatment for rumination syndrome. It works by: Increasing the movement of the stomach and intestines, which may help food move through the digestive system more quickly Potentially reducing the number of times food comes back up into the mouth Possibly improving the function of the lower esophageal sphincter (LES), which is the muscle that prevents stomach contents from flowing back into the esophagus
Current Clinical Trial on Clebopride for Rumination Syndrome
A clinical trial is currently being conducted to evaluate the effectiveness of clebopride in treating rumination syndrome. This trial is important because while clebopride is sometimes used in clinical practice for this condition, there isn't enough scientific evidence yet to prove how well it works.
Key details of the trial include: It's a randomized, double-blind, placebo-controlled, crossover trial. This means that participants will receive both clebopride and a placebo at different times, and neither the participants nor the researchers will know which is being given when. The dose being studied is 0.5 mg of clebopride taken three times a day. The main goal is to see how well patients feel the treatment is working overall. Researchers will also look at how clebopride affects various aspects of digestive function, such as the number of symptom events, the pressure of the lower esophageal sphincter, and the number of times the LES relaxes.
Who Can Participate in the Clinical Trial?
The trial has specific criteria for who can participate. Some key points include: Participants must be at least 18 years old They should have a history consistent with probable rumination syndrome, as assessed by a gastroenterologist They must have had a gastro-duodenoscopy (a type of endoscopy) within the past 12 months showing no abnormalities in the stomach or esophagus that could explain their symptoms Participants must have tried a specific dose of omeprazole (a common acid-reducing medication) for at least 2 weeks before joining the study
There are also several conditions that would prevent someone from participating, such as: Severe erosive esophagitis Pregnancy or breastfeeding Certain psychiatric illnesses History of alcohol or drug abuse Certain systemic diseases that affect esophageal motility Parkinson's syndrome or related conditions Use of certain medications that might interfere with the study
What to Expect During the Trial
If you participate in the trial, you can expect: To take either clebopride or a placebo for a period of time, then switch to the other To undergo tests such as high-resolution impedance manometry (HRiM), which measures pressures and movements in your esophagus To keep a daily symptom diary To complete questionnaires about your symptoms and quality of life
Potential Benefits and Considerations
Participating in this trial could potentially help improve your rumination syndrome symptoms. However, it's important to remember that: The effectiveness of clebopride for rumination syndrome is still being studied You may experience side effects, which your doctor can discuss with you You may receive a placebo for part of the study The study involves several medical procedures and requires a time commitment
Always consult with your healthcare provider to determine if participating in this clinical trial is right for you. They can provide more detailed information about the potential risks and benefits based on your individual health situation.